Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Sinonasal cancer in Denmark 2008-2015: a population-based phase-4 cohort study from DAHANCA

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Filtenborg, MV, Lilja-Fischer, JK, Sharma, MB, Primdahl, H, Kjems, J, Plaschke, CC, Wessel, I, Kristensen, CA, Andersen, M, Andersen, E, Godballe, C, Johansen, J, Overgaard, J & Petersen, KB 2021, 'Sinonasal cancer in Denmark 2008-2015: a population-based phase-4 cohort study from DAHANCA', Acta Oncologica, vol. 60, no. 3, pp. 333-342. https://doi.org/10.1080/0284186X.2021.1874618

APA

Filtenborg, M. V., Lilja-Fischer, J. K., Sharma, M. B., Primdahl, H., Kjems, J., Plaschke, C. C., Wessel, I., Kristensen, C. A., Andersen, M., Andersen, E., Godballe, C., Johansen, J., Overgaard, J., & Petersen, K. B. (2021). Sinonasal cancer in Denmark 2008-2015: a population-based phase-4 cohort study from DAHANCA. Acta Oncologica, 60(3), 333-342. https://doi.org/10.1080/0284186X.2021.1874618

CBE

Filtenborg MV, Lilja-Fischer JK, Sharma MB, Primdahl H, Kjems J, Plaschke CC, Wessel I, Kristensen CA, Andersen M, Andersen E, Godballe C, Johansen J, Overgaard J, Petersen KB. 2021. Sinonasal cancer in Denmark 2008-2015: a population-based phase-4 cohort study from DAHANCA. Acta Oncologica. 60(3):333-342. https://doi.org/10.1080/0284186X.2021.1874618

MLA

Vancouver

Author

Filtenborg, Mads V ; Lilja-Fischer, Jacob K ; Sharma, Maja B ; Primdahl, Hanne ; Kjems, Julie ; Plaschke, Christina C ; Wessel, Irene ; Kristensen, Claus A ; Andersen, Maria ; Andersen, Elo ; Godballe, Christian ; Johansen, Jørgen ; Overgaard, Jens ; Petersen, Kristian B. / Sinonasal cancer in Denmark 2008-2015 : a population-based phase-4 cohort study from DAHANCA. In: Acta Oncologica. 2021 ; Vol. 60, No. 3. pp. 333-342.

Bibtex

@article{8aaf8ccbdac148218418895c6e0abea4,
title = "Sinonasal cancer in Denmark 2008-2015: a population-based phase-4 cohort study from DAHANCA",
abstract = "BACKGROUND: Sinonasal cancer is considered a rare disease with poor survival. Its treatment has changed profoundly in recent years, primarily following the introduction of intensity-modulated radiation therapy (IMRT) and minimally invasive endoscopic surgery. Danish national guidelines on treatment of patients diagnosed with sinonasal carcinoma were introduced in 2007. The aim of this phase-4 study was to assess the effect of the implementation of guidelines by describing treatment outcomes in a consecutive nationwide cohort.METHODS: All patients diagnosed with sinonasal carcinoma in Denmark from 2008 to 2015 were identified in the nationwide clinical database, DAHANCA, and were followed until May 2020. Overall survival (OS) was analysed using Kaplan-Meier estimator. Cumulative incidence of locoregional failure (LRF) and disease-specific mortality (DSM) were analysed using the Aalen-Johansen estimator. Competing risks were death from other causes (DSM) and distant failure and death (LRF). Analysis of prognostic factors was performed using Cox proportional hazard analysis. Start of follow-up was time of diagnosis. The results are presented as estimates with 95% confidence intervals (95% CIs).RESULTS: A total of 331 patients were identified. Curatively intended treatment was performed in 264 patients (80%). Non-compliance with treatment guidelines was registered in 24 patients (9%). Non-compliance was associated with LRF (hazard ratio [HR], 2.0 [95% CI: 1.1-3.5]). Among patients qualified for curative treatment, failure occurred in 109 patients (41%), primarily at the primary tumour site (81%). Anatomical tumour site and disease stage were independent prognostic factors. The 5-year OS was 56% in patients treated with curative intent, and a combined treatment strategy showed reduced LRF (HR, 0.53 [95% CI: 0.30-0.92]) in a multivariate analysis.CONCLUSIONS: Guideline compliance and a combined treatment approach reduced the incidence of LRF and thereby increased OS. Our results confirm those of international studies. Treatment of sinonasal carcinoma remains a challenge that requires multidisciplinary team coordination.",
keywords = "Sinonasal carcinoma, guidelines, national population study, phase-4, treatment outcome",
author = "Filtenborg, {Mads V} and Lilja-Fischer, {Jacob K} and Sharma, {Maja B} and Hanne Primdahl and Julie Kjems and Plaschke, {Christina C} and Irene Wessel and Kristensen, {Claus A} and Maria Andersen and Elo Andersen and Christian Godballe and J{\o}rgen Johansen and Jens Overgaard and Petersen, {Kristian B}",
note = "Publisher Copyright: {\textcopyright} 2021 Acta Oncologica Foundation. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = mar,
doi = "10.1080/0284186X.2021.1874618",
language = "English",
volume = "60",
pages = "333--342",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "3",

}

RIS

TY - JOUR

T1 - Sinonasal cancer in Denmark 2008-2015

T2 - a population-based phase-4 cohort study from DAHANCA

AU - Filtenborg, Mads V

AU - Lilja-Fischer, Jacob K

AU - Sharma, Maja B

AU - Primdahl, Hanne

AU - Kjems, Julie

AU - Plaschke, Christina C

AU - Wessel, Irene

AU - Kristensen, Claus A

AU - Andersen, Maria

AU - Andersen, Elo

AU - Godballe, Christian

AU - Johansen, Jørgen

AU - Overgaard, Jens

AU - Petersen, Kristian B

N1 - Publisher Copyright: © 2021 Acta Oncologica Foundation. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/3

Y1 - 2021/3

N2 - BACKGROUND: Sinonasal cancer is considered a rare disease with poor survival. Its treatment has changed profoundly in recent years, primarily following the introduction of intensity-modulated radiation therapy (IMRT) and minimally invasive endoscopic surgery. Danish national guidelines on treatment of patients diagnosed with sinonasal carcinoma were introduced in 2007. The aim of this phase-4 study was to assess the effect of the implementation of guidelines by describing treatment outcomes in a consecutive nationwide cohort.METHODS: All patients diagnosed with sinonasal carcinoma in Denmark from 2008 to 2015 were identified in the nationwide clinical database, DAHANCA, and were followed until May 2020. Overall survival (OS) was analysed using Kaplan-Meier estimator. Cumulative incidence of locoregional failure (LRF) and disease-specific mortality (DSM) were analysed using the Aalen-Johansen estimator. Competing risks were death from other causes (DSM) and distant failure and death (LRF). Analysis of prognostic factors was performed using Cox proportional hazard analysis. Start of follow-up was time of diagnosis. The results are presented as estimates with 95% confidence intervals (95% CIs).RESULTS: A total of 331 patients were identified. Curatively intended treatment was performed in 264 patients (80%). Non-compliance with treatment guidelines was registered in 24 patients (9%). Non-compliance was associated with LRF (hazard ratio [HR], 2.0 [95% CI: 1.1-3.5]). Among patients qualified for curative treatment, failure occurred in 109 patients (41%), primarily at the primary tumour site (81%). Anatomical tumour site and disease stage were independent prognostic factors. The 5-year OS was 56% in patients treated with curative intent, and a combined treatment strategy showed reduced LRF (HR, 0.53 [95% CI: 0.30-0.92]) in a multivariate analysis.CONCLUSIONS: Guideline compliance and a combined treatment approach reduced the incidence of LRF and thereby increased OS. Our results confirm those of international studies. Treatment of sinonasal carcinoma remains a challenge that requires multidisciplinary team coordination.

AB - BACKGROUND: Sinonasal cancer is considered a rare disease with poor survival. Its treatment has changed profoundly in recent years, primarily following the introduction of intensity-modulated radiation therapy (IMRT) and minimally invasive endoscopic surgery. Danish national guidelines on treatment of patients diagnosed with sinonasal carcinoma were introduced in 2007. The aim of this phase-4 study was to assess the effect of the implementation of guidelines by describing treatment outcomes in a consecutive nationwide cohort.METHODS: All patients diagnosed with sinonasal carcinoma in Denmark from 2008 to 2015 were identified in the nationwide clinical database, DAHANCA, and were followed until May 2020. Overall survival (OS) was analysed using Kaplan-Meier estimator. Cumulative incidence of locoregional failure (LRF) and disease-specific mortality (DSM) were analysed using the Aalen-Johansen estimator. Competing risks were death from other causes (DSM) and distant failure and death (LRF). Analysis of prognostic factors was performed using Cox proportional hazard analysis. Start of follow-up was time of diagnosis. The results are presented as estimates with 95% confidence intervals (95% CIs).RESULTS: A total of 331 patients were identified. Curatively intended treatment was performed in 264 patients (80%). Non-compliance with treatment guidelines was registered in 24 patients (9%). Non-compliance was associated with LRF (hazard ratio [HR], 2.0 [95% CI: 1.1-3.5]). Among patients qualified for curative treatment, failure occurred in 109 patients (41%), primarily at the primary tumour site (81%). Anatomical tumour site and disease stage were independent prognostic factors. The 5-year OS was 56% in patients treated with curative intent, and a combined treatment strategy showed reduced LRF (HR, 0.53 [95% CI: 0.30-0.92]) in a multivariate analysis.CONCLUSIONS: Guideline compliance and a combined treatment approach reduced the incidence of LRF and thereby increased OS. Our results confirm those of international studies. Treatment of sinonasal carcinoma remains a challenge that requires multidisciplinary team coordination.

KW - Sinonasal carcinoma

KW - guidelines

KW - national population study

KW - phase-4

KW - treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=85100802640&partnerID=8YFLogxK

U2 - 10.1080/0284186X.2021.1874618

DO - 10.1080/0284186X.2021.1874618

M3 - Journal article

C2 - 33544640

VL - 60

SP - 333

EP - 342

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 3

ER -

ID: 65605926